Januvia (Sitagliptin)

Sitagliptin, most commonly known by its brand name Januvia, is an oral diabetes medicine that helps control blood sugar levels. It was developed by the American pharmaceutical giant Merck & Co., Inc. following its discovery of the DPP-4 inhibitor class of medications.

While the brand originated in the United States, Januvia is manufactured across a global network of Merck facilities to meet international demand. Major production sites have historically included locations in the United States, Puerto Rico, and various European hubs. As a leading treatment for type 2 diabetes, the product is distributed globally through Merck's extensive network of regional subsidiaries and local partners, maintaining a dominant position in the metabolic health market.